Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
25 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Délais de RDV courts dans la région
129.9 rhumatos / 100 000 hab. — département bien doté
46 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
23
23 articles ont été cités au moins 23fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
2 433
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
101
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
35
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Nantes Université
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients
2026ArticleFrontiers in Immunology
Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology
2026ArticleMolecular Cancer
Indications and contraindications to platelet‐rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections)
2025ArticleKnee Surgery, Sports Traumatology, Arthroscopy
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)
2025ArticleCancer Immunology, Immunotherapy
Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment
2024ArticleOncoImmunology
Concomitant ALK translocation and EGFR C797S mutation as resistance mechanisms to osimertinib in an EGFR-mutant NSCLC patient
2024ArticleRespiratory Medicine and Research
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
2024ArticleRespiratory Research
Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study
2024ArticleLung Cancer
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHU DE NANTES SITE LAENNEC
BD JACQUES MONOD, 44800 ST HERBLAIN
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
PURPOSE Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human epidermal growth factor receptor 2–mutant ( HER2m; defined as single-nucleotide variants and exon 20 insertions) metastatic non–small-cell lung cancer (mNSCLC). METHODS DESTINY-Lung02, a blinded, multicenter, phase II study, investigated T-DXd 5.4 mg/kg once every 3 weeks for the first time in previously treated (platinum-containing therapy) patients with HER2m mNSCLC and further assessed T-DXd 6.4 mg/kg once every 3 weeks in this population. The primary end point was confirmed objective response rate (ORR) per RECIST v1.1 by blinded independent central review. RESULTS One hundred fifty-two patients were randomly assigned 2:1 to T-DXd 5.4 or 6.4 mg/kg once every 3 weeks. As of December 23, 2022, the median duration of follow-up was 11.5 months (range, 1.1-20.6) with 5.4 mg/kg and 11.8 months (range, 0.6-21.0) with 6.4 mg/kg. Confirmed ORR was 49.0% (95% CI, 39.0 to 59.1) and 56.0% (95% CI, 41.3 to 70.0) and median duration of response was 16.8 months (95% CI, 6.4 to not estimable [NE]) and NE (95% CI, 8.3 to NE) with 5.4 and 6.4 mg/kg, respectively. Median treatment duration was 7.7 months (range, 0.7-20.8) with 5.4 mg/kg and 8.3 months (range, 0.7-20.3) with 6.4 mg/kg. Grade ≥ 3 drug-related treatment-emergent adverse events occurred in 39 of 101 (38.6%) and 29 of 50 (58.0%) patients with 5.4 and 6.4 mg/kg, respectively. 13 of 101 (12.9%) and 14 of 50 (28.0%) patients had adjudicated drug-related interstitial lung disease (2.0% grade ≥ 3 in each arm) with 5.4 and 6.4 mg/kg, respectively. CONCLUSION T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
PURPOSE The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in patients with pretreated advanced/metastatic non–small cell lung cancer (NSCLC). METHODS Patients received Dato-DXd 6 mg/kg or docetaxel 75 mg/m 2 once every 3 weeks. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Objective response rate, duration of response, and safety were secondary end points. RESULTS In total, 299 and 305 patients were randomly assigned to receive Dato-DXd or docetaxel, respectively. The median PFS was 4.4 months (95% CI, 4.2 to 5.6) with Dato-DXd and 3.7 months (95% CI, 2.9 to 4.2) with docetaxel (hazard ratio [HR], 0.75 [95% CI, 0.62 to 0.91]; P = .004). The median OS was 12.9 months (95% CI, 11.0 to 13.9) and 11.8 months (95% CI, 10.1 to 12.8), respectively (HR, 0.94 [95% CI, 0.78 to 1.14]; P = .530). In the prespecified nonsquamous histology subgroup, the median PFS was 5.5 versus 3.6 months (HR, 0.63 [95% CI, 0.51 to 0.79]) and the median OS was 14.6 versus 12.3 months (HR, 0.84 [95% CI, 0.68 to 1.05]). In the squamous histology subgroup, the median PFS was 2.8 versus 3.9 months (HR, 1.41 [95% CI, 0.95 to 2.08]) and the median OS was 7.6 versus 9.4 months (HR, 1.32 [95% CI, 0.91 to 1.92]). Grade ≥3 treatment-related adverse events occurred in 25.6% and 42.1% of patients, and any-grade adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8.8% and 4.1% of patients, in the Dato-DXd and docetaxel groups, respectively. CONCLUSION Dato-DXd significantly improved PFS versus docetaxel in patients with advanced/metastatic NSCLC, driven by patients with nonsquamous histology. OS showed a numerical benefit but did not reach statistical significance. No unexpected safety signals were observed.
Nature medicine · 2024
AbstractFor patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance—which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment—and developing effective therapies to overcome them, remains an unmet need. Here the phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy. A total of 268 patients received durvalumab (anti-PD-L1 monoclonal antibody)–ceralasertib (ATR kinase inhibitor), durvalumab–olaparib (PARP inhibitor), durvalumab–danvatirsen (STAT3 antisense oligonucleotide) or durvalumab–oleclumab (anti-CD73 monoclonal antibody). Greatest clinical benefit was observed with durvalumab–ceralasertib; objective response rate (primary outcome) was 13.9% (11/79) versus 2.6% (5/189) with other regimens, pooled, median progression-free survival (secondary outcome) was 5.8 (80% confidence interval 4.6–7.4) versus 2.7 (1.8–2.8) months, and median overall survival (secondary outcome) was 17.4 (14.1–20.3) versus 9.4 (7.5–10.6) months. Benefit with durvalumab–ceralasertib was consistent across known immunotherapy-refractory subgroups. In ATM-altered patients hypothesized to harbor vulnerability to ATR inhibition, objective response rate was 26.1% (6/23) and median progression-free survival/median overall survival were 8.4/22.8 months. Durvalumab–ceralasertib safety/tolerability profile was manageable. Biomarker analyses suggested that anti-PD-L1/ATR inhibition induced immune changes that reinvigorated antitumor immunity. Durvalumab–ceralasertib is under further investigation in immunotherapy-refractory NSCLC.ClinicalTrials.gov identifier: NCT03334617
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Bulletin du cancer · 2026 · Journal Article
Cap M, Nael V, Mouézy L, Fourage L, et al.
Respiratory medicine and research · 2024 · Journal Article
Pons-Tostivint E, Hulo P, Sagan C, Papazyan T, et al.
Lung cancer (Amsterdam, Netherlands) · 2024 · Journal Article
Pons-Tostivint E, Ezzedine R, Goronflot T, Crequit P, et al.
Lung cancer (Amsterdam, Netherlands) · 2023 · Journal Article
Nigen B, Goronflot T, Herbreteau G, Mathiot L, et al.
Translational lung cancer research · 2023 · Editorial
Denis MG, Herbreteau G, Pons-Tostivint E
Annals of surgery · 2023 · Clinical Trial
Hotton J, Lusque A, Leufflen L, Campone M, et al.
European journal of cancer care · 2022 · Journal Article
Martinez A, Daubisse-Marliac L, Lacaze JL, Pons-Tostivint E, et al.
Current oncology (Toronto, Ont.) · 2022 · Editorial
Pons-Tostivint E, Bennouna J
EMBO molecular medicine · 2021 · Journal Article
Thibault B, Ramos-Delgado F, Pons-Tostivint E, Therville N, et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020 · Journal Article
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · Published Erratum
Jänne PA, Goto Y, Kubo T, Ninomiya K, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · Journal Article
Jänne PA, Goto Y, Kubo T, Ninomiya K, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Cancer immunology, immunotherapy : CII · 2025 · Journal Article
Costantini A, Takam Kamga P, Pons-Tostivint E, Fradin D, et al.
Nature medicine · 2024 · Clinical Trial, Phase II
Besse B, Pons-Tostivint E, Park K, Hartl S, et al.
Clinical and translational science · 2024 · Clinical Trial, Phase I
IDCases · 2022 · Case Reports
Mandin V, Corvec S, Chéné AL, Guillouzouic A, et al.
Current oncology (Toronto, Ont.) · 2022 · Case Reports
Mathiot L, Herbreteau G, Robin S, Fenat C, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026 · Published Erratum
Jänne PA, Goto Y, Kubo T, Ninomiya K, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025 · Journal Article
Jänne PA, Goto Y, Kubo T, Ninomiya K, et al.
Translational lung cancer research · 2026 · Journal Article
Robert M, Sauzay C, Théoleyre S, Vallée A, et al.
Current oncology (Toronto, Ont.) · 2022 · Case Reports
Mathiot L, Herbreteau G, Robin S, Fenat C, et al.
Annals of surgical oncology · 2019 · Comparative Study
Pons-Tostivint E, Kirova Y, Lusque A, Campone M, et al.
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2025 · Consensus Statement
Eymard F, Louati K, Noel É, Abouqal R, et al.
Clinical lung cancer · 2024 · Multicenter Study
Porte M, Vaudron A, Crequit P, Vaugier L, et al.
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Abstract Background Lung cancers represent the main cause of cancer related-death worldwide. Recently, immunotherapy alone or in combination with chemotherapy has deeply impacted the therapeutic care leading to an improv
Additional file 1 of Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Supplementary Figure S1: Number of genes regulated specifically and in common by CaPa and CaGe treatments. A) Left, vendiagramm showing the number of genes upregulated in common or specifically after CaPa or CaGe treatme
Additional file 3 of Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Supplementary Figure S3: PD-L1 (CD274) expression is not induced in fibroblasts and macrophages following treatment. Lung cancer cells, ADCA117 (GFP +), fibroblasts (HFF-2) and monocytes were grown as MCTS. MCTS were tre
Additional file 2 of Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Supplementary Figure S2: PD-L1 (CD274) expression is induced following carboplatin-paclitaxel exposure in complex MCTS. Lung cancer cells, ADCA117, alone (A) or with fibroblasts (HFF-2) and monocytes (B) were grown as MC
Additional file 2 of Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Supplementary Figure S2: PD-L1 (CD274) expression is induced following carboplatin-paclitaxel exposure in complex MCTS. Lung cancer cells, ADCA117, alone (A) or with fibroblasts (HFF-2) and monocytes (B) were grown as MC
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Abstract Background Lung cancers represent the main cause of cancer related-death worldwide. Recently, immunotherapy alone or in combination with chemotherapy has deeply impacted the therapeutic care leading to an improv
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Sands J, Ahn MJ, Lisberg A, Cho BC, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · Journal Article
Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · Clinical Trial, Phase II
Goto K, Goto Y, Kubo T, Ninomiya K, et al.
JCO precision oncology · 2019 · Journal Article
Pons-Tostivint E, Latouche A, Vaflard P, Ricci F, et al.
Robbrecht D, Grob JJ, Bechter O, Simonelli M, et al.